Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

11/06/2025 - 08:34 PM

New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management.

MONTREAL--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l’assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*.

Quebec residents with type 2 diabetes on intensive insulin therapy are now covered for Dexcom CGM through RAMQ.

According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of those living with diabetes, and many eventually require insulin when lifestyle changes and oral medications are no longer enough to manage blood glucose¹. The expansion of RAMQ coverage will grant access to Dexcom CGM for a broader population.

“This announcement represents a significant step forward for people managing diabetes in Québec and their healthcare providers, with broader access to Dexcom’s advanced CGM technology,” says André Côté, Vice President and General Manager of Dexcom Canada. “Dexcom G7 is the most accurate CGM System^†,2, and the #1 preferred CGM by Canadian endocrinologists.^‡,3 88% of CGM users with type 2 diabetes reported it helped them better understand and adjust their lifestyle⁴ and the impact on their daily diabetes management was both meaningful and measurable.”

Régie de l'assurance maladie du Québec (RAMQ) – individuals must be aged two and older and meet the following criteria:

Under age 18: Must have type 1 diabetes.
Age 18 and over: Must be on intensive insulin therapy (at least three injections/day or insulin pump) and meet one or more of the following:
- Hemoglobin A1C target not achieved despite optimal disease management
- Frequent hypoglycemia episodes in the past year despite adherence to a glycemia plan
- Inability to recognize or signal symptoms of hypoglycemia

Private Insurance – All private insurance plans must offer coverage that is at least equivalent or better than the RAMQ criteria. Most private insurance plans already cover Dexcom CGM for anyone on insulin and some plans cover anyone with diabetes.

With Dexcom CGM sensors, individuals can track glucose levels in real time, learn how treatments and daily choices affect their body, and discover what helps them stay in target glucose range, empowering them to feel their best and stay motivated.

“In clinical practice, continuous glucose monitoring has significantly advanced our ability to personalize diabetes care,” says Dr. Yves Robitaille, Specialist in Internal Medicine and Medical Director at the Metabolic Medicine Center of Lanaudière. “Offering patients a range of options ensures that treatment aligns with their specific health goals and circumstances.”

Discreet and easy to use, Dexcom G7 is the only CGM system in Canada to offer these features for insulin therapy optimization and personalization:

Predictive Urgent Low Soon^§alert that can warn in advance of severe hypoglycemia⁵
Delay 1^st High alert after a meal that may help reduce insulin stacking^6,7
Waterproof sensor^||
Fast 30-minute sensor warm-up time
Multiple sensor wear locations
Direct to Apple Watch functionality^#– user can see glucose numbers right on their wrist

As the #1 patient recommended CGM in Canada^**,8, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Québecers than ever will have access to this technology for their diabetes management.

To learn more about Dexcom CGM and the public and private coverage options available, please visit dexcom.com.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of.

For more information, visit www.dexcom.com.

Category: IR

* https://www.dexcom.com/en-CA/coverage/quebec-ramq-provincial-cgm-coverage

† When compared with CGM systems commercially available in Canada as of October 2025. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen.

^‡ Based on a survey of Canadian Endocrinologists (n=41)

§ Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes.

|| The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed.

Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old.

# Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch.

** Based on a comparison in NPS scores across major CGM brands

1 https://www.diabete.qc.ca/en/diabetes/information-on-diabetes/type-2-diabetes/

2 Dexcom, data on file, 2025

3 Q&A, Dexcom Canadian Endos Report Wave 1 2024

4 Dexcom, Data on File, 2024.

5 Dexcom G7 User Guide.

6 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255.

7 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158.

8 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024